 "Sanofi Pasteur and MSD end vaccines JV in Europe")
Sanofi Pasteur and MSD, known as Merck in the US and Canada, on March 8, 2016 have agreed to end their joint vaccines operations in Europe. Upon concluding their joint venture, both companies plan to integrate their respective European vaccine businesses into their operations, independently manage their product portfolios and pursue their own distinct growth strategies in Europe.
The 50:50 joint venture Sanofi Pasteur MSD was created in 1994 to develop and commercialise vaccines originating from both companies’ pipelines to improve and promote public health in 19 European countries. Over the past twenty years, Sanofi Pasteur MSD has launched numerous innovative vaccines originating from the development pipelines of Sanofi Pasteur and MSD, addressing key unmet medical needs and helping to protect millions of lives.
Sanofi Pasteur and MSD expect the project to be completed by the end of 2016, subject to local labour laws and regulations and regulatory approvals.
The 50:50 joint venture Sanofi Pasteur MSD was created in 1994 to develop and commercialise vaccines originating from both companies’ pipelines to improve and promote public health in 19 European countries. Over the past twenty years, Sanofi Pasteur MSD has launched numerous innovative vaccines originating from the development pipelines of Sanofi Pasteur and MSD, addressing key unmet medical needs and helping to protect millions of lives.
Sanofi Pasteur and MSD expect the project to be completed by the end of 2016, subject to local labour laws and regulations and regulatory approvals.